Articles

• Proceedings of the International Symposium on Aromatase and its Inhibition: New Biology and Clinical Perspectives. Prague, Czech Republic. 3-6 September 1998.

  Endocr Relat Cancer 6 (2) 127-333, doi:10.1677/erc.0.0060127
  • Citation Only
• • W R Miller

  Aromatase and its inhibitors: new biology and clinical perspectives.

  Endocr Relat Cancer 6 (2) 127-30, doi:10.1677/erc.0.006a127
  • Full Text (PDF)
• Select this article
  • E Simpson,
  • G Rubin,
  • C Clyne,
  • K Robertson,
  • L O'Donnell,
  • S Davis,
  • and M Jones

  Local estrogen biosynthesis in males and females.

  Endocr Relat Cancer 6 (2) 131-7, doi:10.1677/erc.0.0060131
  • Abstract
  • Full Text (PDF)
• Select this article
  • A Singh,
  • A Purohit,
  • M W Ghilchik,
  • and M J Reed

  The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2.

  Endocr Relat Cancer 6 (2) 139-47, doi:10.1677/erc.0.0060139
  • Abstract
  • Full Text (PDF)
• Select this article
  • S Chen,
  • D Zhou,
  • T Okubo,
  • Y C Kao,
  • and C Yang

  Breast tumor aromatase: functional role and transcriptional regulation.

  Endocr Relat Cancer 6 (2) 149-56, doi:10.1677/erc.0.0060149
  • Abstract
  • Full Text (PDF)
• Select this article
  • W Yue,
  • R J Santen,
  • J P Wang,
  • C J Hamilton,
  • and L M Demers

  Aromatase within the breast.

  Endocr Relat Cancer 6 (2) 157-64, doi:10.1677/erc.0.0060157
  • Abstract
  • Full Text (PDF)
• Select this article
  • N M Probst-Hensch,
  • S A Ingles,
  • A T Diep,
  • R W Haile,
  • F Z Stanczyk,
  • L N Kolonel,
  • and B E Henderson

  Aromatase and breast cancer susceptibility.

  Endocr Relat Cancer 6 (2) 165-73, doi:10.1677/erc.0.0060165
  • Abstract
  • Full Text (PDF)
• Select this article
  • T J Key

  Serum oestradiol and breast cancer risk.

  Endocr Relat Cancer 6 (2) 175-80, doi:10.1677/erc.0.0060175
  • Abstract
  • Full Text (PDF)
• Select this article
  • M Dowsett

  Drug and hormone interactions of aromatase inhibitors.

  Endocr Relat Cancer 6 (2) 181-5, doi:10.1677/erc.0.0060181
  • Abstract
  • Full Text (PDF)
• Select this article
  • W R Miller

  Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.

  Endocr Relat Cancer 6 (2) 187-95, doi:10.1677/erc.0.0060187
  • Abstract
  • Full Text (PDF)
• Select this article
  • H Sasano,
  • S Sato,
  • K Ito,
  • A Yajima,
  • J Nakamura,
  • M Yoshihama,
  • K Ariga,
  • T J Anderson,
  • and W R Miller

  Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma.

  Endocr Relat Cancer 6 (2) 197-204, doi:10.1677/erc.0.0060197
  • Abstract
  • Full Text (PDF)
• Select this article
  • A Brodie,
  • Q Lu,
  • Y Liu,
  • and B Long

  Aromatase inhibitors and their antitumor effects in model systems.

  Endocr Relat Cancer 6 (2) 205-10, doi:10.1677/erc.0.0060205
  • Abstract
  • Full Text (PDF)
• Select this article
  • N Harada,
  • S I Honda,
  • and O Hatano

  Aromatase inhibitors and enzyme stability.

  Endocr Relat Cancer 6 (2) 211-8, doi:10.1677/erc.0.0060211
  • Abstract
  • Full Text (PDF)
• Select this article
  • A U Buzdar

  Role of aromatase inhibitors in advanced breast cancer.

  Endocr Relat Cancer 6 (2) 219-25, doi:10.1677/erc.0.0060219
  • Abstract
  • Full Text (PDF)
• Select this article
  • J M Dixon,
  • C D Love,
  • L Renshaw,
  • C Bellamy,
  • D A Cameron,
  • W R Miller,
  • and R C Leonard

  Lessons from the use of aromatase inhibitors in the neoadjuvant setting.

  Endocr Relat Cancer 6 (2) 227-30, doi:10.1677/erc.0.0060227
  • Abstract
  • Full Text (PDF)
• Select this article
  • M Baum

  Use of aromatase inhibitors in the adjuvant treatment of breast cancer.

  Endocr Relat Cancer 6 (2) 231-4, doi:10.1677/erc.0.0060231
  • Abstract
  • Full Text (PDF)
• Select this article
  • R J Santen,
  • W Yue,
  • F Naftolin,
  • G Mor,
  • and L Berstein

  The potential of aromatase inhibitors in breast cancer prevention.

  Endocr Relat Cancer 6 (2) 235-43, doi:10.1677/erc.0.0060235
  • Abstract
  • Full Text (PDF)
• • I E Smith

  Aromatase inhibitors: a dose-response effect?

  Endocr Relat Cancer 6 (2) 245-9, doi:10.1677/erc.0.0060245
  • Full Text (PDF)
• Select this article
  • P E L√∏nning

  Cross-resistance to different aromatase inhibitors in breast cancer treatment.

  Endocr Relat Cancer 6 (2) 251-7, doi:10.1677/erc.0.0060251
  • Abstract
  • Full Text (PDF)
• Select this article
  • R C Coombes,
  • C Harper-Wynne,
  • and M Dowsett

  Aromatase inhibitors and their use in the sequential setting.

  Endocr Relat Cancer 6 (2) 259-63, doi:10.1677/erc.0.0060259
  • Abstract
  • Full Text (PDF)
• Select this article
  • J N Ingle,
  • V J Suman,
  • V C Jordan,
  • and M Dowsett

  Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.

  Endocr Relat Cancer 6 (2) 265-9, doi:10.1677/erc.0.0060265
  • Abstract
  • Full Text (PDF)
• Select this article
  • C K Osborne

  Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.

  Endocr Relat Cancer 6 (2) 271-6, doi:10.1677/erc.0.0060271
  • Abstract
  • Full Text (PDF)
• Select this article
  • J Ragaz

  Status of aromatase inhibitors in relation to other breast cancer treatment modalities.

  Endocr Relat Cancer 6 (2) 277-91, doi:10.1677/erc.0.0060277
  • Abstract
  • Full Text (PDF)
• Select this article
  • S E Bulun,
  • K Zeitoun,
  • K Takayama,
  • L Noble,
  • D Michael,
  • E Simpson,
  • A Johns,
  • M Putman,
  • and H Sasano

  Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis.

  Endocr Relat Cancer 6 (2) 293-301, doi:10.1677/erc.0.0060293
  • Abstract
  • Full Text (PDF)
• Select this article
  • P Feuillan,
  • D Merke,
  • E W Leschek,
  • and G B Cutler, Jr

  Use of aromatase inhibitors in precocious puberty.

  Endocr Relat Cancer 6 (2) 303-6, doi:10.1677/erc.0.0060303
  • Abstract
  • Full Text (PDF)
• Select this article
  • R R Tekmal,
  • N Kirma,
  • K Gill,
  • and K Fowler

  Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.

  Endocr Relat Cancer 6 (2) 307-14, doi:10.1677/erc.0.0060307
  • Abstract
  • Full Text (PDF)
• Select this article
  • G D Braunstein

  Aromatase and gynecomastia.

  Endocr Relat Cancer 6 (2) 315-24, doi:10.1677/erc.0.0060315
  • Abstract
  • Full Text (PDF)
• Select this article
  • P E Goss

  Risks versus benefits in the clinical application of aromatase inhibitors.

  Endocr Relat Cancer 6 (2) 325-32, doi:10.1677/erc.0.0060325
  • Abstract
  • Full Text (PDF)